With the finishing line close for its two key investigational products, Zealand Pharma AS of Denmark is accelerating the build-up of US operations and preparing for its transition into a commercial-stage company in 2020.
US Is Land Of Opportunity For Zealand
The Danish group is beefing up its operations across the Atlantic as it prepares filings for dasiglucagon and glepaglutide.
